Results 191 to 200 of about 353,208 (291)

Dasatinib and quercetin prevent alveolar bone loss in aged mice

open access: yesJournal of Periodontology, EarlyView.
Abstract Background Recent findings have associated alveolar bone loss (ABL) with the presence of senescent cells. Aging and the accumulation of senescent cells are associated with a pro‐inflammatory environment which may exacerbate tissue damage.
Luisa S. Battistelli   +7 more
wiley   +1 more source

Intramuscular lipoma of tongue

open access: yesJournal of Cutaneous and Aesthetic Surgery, 2011
Garg, Monika   +4 more
openaire   +2 more sources

Severe allergic reaction to ustekinumab reinitiation in a pediatric patient with Crohn's disease: A case report

open access: yesJPGN Reports, EarlyView.
Abstract Ustekinumab (UST) is a monoclonal antibody used in the management of moderate to severe inflammatory bowel disease. While generally well‐tolerated, serious adverse reactions, including hypersensitivity and anaphylaxis, have been documented, specifical following the initial intravenous (IV) dose.
Kennedy Sparling   +2 more
wiley   +1 more source

Comparison of the Application Value of 4‐Dimensional Hysterosalpingo‐Contrast Sonography and X‐Ray Hysterosalpingography in Intrauterine Insemination

open access: yesJournal of Ultrasound in Medicine, EarlyView.
Objectives To compare the application value of 4‐dimensional hysterosalpingo‐contrast sonography (4D‐HyCoSy) and x‐ray hysterosalpingography (HSG) in intrauterine insemination (IUI) patients. Methods In this retrospective study, a total of 725 infertile patients who underwent IUI in Ganzhou Maternal and Child Health Hospital from January 2023 to June ...
Yongyu Xie   +3 more
wiley   +1 more source

Characteristics and Clinical Outcomes of Patients With Hidradenitis Suppurativa (HS) Treated With Bimekizumab: A Canadian Retrospective Chart Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy